天津医药

天津医药 ›› 2018, Vol. 46 ›› Issue (12): 1363-1368.doi: 10.11958/20181045

• 综述 • 上一篇    

三阴性乳腺癌靶向治疗研究进展

刘蕾，张瑾   

  1. 天津医科大学肿瘤医院乳腺三科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，乳腺癌防治教育部重点实验室（邮编300060）
  • 收稿日期:2018-07-10 修回日期:2018-10-24 出版日期:2018-12-15 发布日期:2019-01-24
  • 通讯作者: 张瑾 E-mail:zhangjin@tjmuch.com

Research progress on targeted therapy of triple negative breast cancer

LIU Lei,ZHANG Jin   

  1. The Third Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center of Cancer,Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education, Tianjin 300060, China
  • Received:2018-07-10 Revised:2018-10-24 Published:2018-12-15 Online:2019-01-24

PDF (PC)

4820

摘要： 三阴性乳腺癌（TNBC）作为乳腺癌一种预后较差的亚型，在出现化疗药物抵抗的情况下，由于缺少其他有效治疗方法，疾病往往易快速复发转移。因此针对TNBC新治疗靶点及靶向药物的研究已成为目前国内外研究热点。本文主要针对目前TNBC靶向治疗研究进展进行总结分析，主要包括ADP合同聚合酶抑制剂、抗血管生成靶向药物、抗表皮生长因子受体信号通路靶向药物、雄激素受体拮抗剂、免疫检查点抑制剂、PI3K-AKT-mTOR通路抑制剂等，以期从中找出最有可能成为未来发展方向的靶向治疗方法。

关键词: 三阴性乳腺癌, 靶向治疗, 综述

Abstract: As a subtype of breast cancer, triple negative breast cancer (TNBC) is characterized by poor prognosis. In the case of chemotherapeutic drug resistance, local recurrence and distant metastasis always occur rapidly due to lack of other effective treatments. Therefore, clinical research on new therapeutic target and targeted therapy of TNBC has become a hot spot. This paper focused on the current research progress of TNBC targeted therapy, including PARP inhibitors, antiangiogenesis, anti-epidermal growth factor receptor, androgen receptor antagonists, immune checkpoint inhibitors and PI3KAKT-mTOR inhibitors, in order to find out the most likely to be the direction of targeted therapy for future development.

Key words: triple negative breast cancer, targeted therapy, review